B

    Bright Minds Biosciences Inc (DRUG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $71.73
    -1.08 (-1.48%)

    Market Cap: $714.42M

    Last updated: Aug 31, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    100%(8/8)
    Avg Surprise
    +47.14%
    Streak
    8 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.43
    Range$-0.39 - $1.23
    6 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    Dec 31, 2026
    EPS Consensus$-1.84
    Range$-2.72 - $-1.21
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate Drift
    90d ago$-2.78-51.1%
    60d ago$-2.78-51.4%
    30d ago$-2.78-51.4%
    7d ago$-2.78-51.4%
    Current$-1.84
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.84---
    Sep 26EST
    		-$0.43---
    Jun 26
    		$-0.17N/A+87.77%Beat+77.0%
    Mar 26
    		$-1.09$-1.26+13.49%Beat-275.9%
    Dec 25
    		$-0.97$-1.18+17.80%Beat-9800.0%
    Sep 25
    		$-0.57$-1.00+42.86%Beat-235.3%
    Jun 25
    		$-0.74$-0.88+15.91%Beat-2149.9%
    Mar 25
    		$-0.29$-0.39+25.64%Beat-204.0%
    Dec 24
    		$0.01N/A+102.00%Beat+103.1%
    Sep 24
    		$-0.17N/A+71.67%Beat+43.7%
    Jun 24
    		$0.04N/AN/ABeat+112.5%
    Mar 24
    		$-0.10N/AN/ABeat-19.1%
    Dec 23
    		$-0.32N/AN/ABeat-235.6%
    Sep 23
    		$-0.30N/AN/ABeat-98.7%
    Jun 23
    		$-0.29$0.00N/AMiss-69.0%
    Mar 23
    		$-0.08$0.00N/AMiss+72.9%
    Dec 22
    		$-0.10$0.00N/AMiss+70.5%
    Sep 22
    		$-0.15$0.00N/AMiss+36.7%
    Jun 22
    		$-0.17N/AN/ABeat+29.9%
    Mar 22
    		$-0.30N/AN/ABeat-132.4%
    Dec 21
    		$-0.33N/AN/ABeat-
    Sep 21
    		$-0.24N/AN/ABeat-
    Jun 21
    		$-0.24N/AN/ABeat-
    Mar 21
    		$-0.13N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-34.66EV/EBITDA-0.07x
    Price/FCF-43.68xFCF Yield-2.29%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-13.60%ROIC-6.47%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio121.97xQuick Ratio121.97x
    Trading Statistics
    Beta0.09Avg Volume146.18K
    52-Week High$123.7552-Week Low$38.00

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$77.70
    SMA 20$78.44
    SMA 50$74.13
    SMA 200$77.65
    EMA 10$76.03
    EMA 20$76.68
    EMA 50$75.85
    EMA 200$72.15

    MACD

    Line: -0.15Signal: 0.99Hist: -1.14

    ADX

    ADX: 14.2+DI: 21.9-DI: 30.9

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down8.0
    PSAR$83.69

    Bollinger Bands

    Upper Band$84.85
    Lower Band$72.03
    %B Position1635%(Upper)
    Band Width-0.02

    RSI (14-Day)

    Neutral
    40.9

    Momentum Oscillators

    Stoch %K4.8
    Stoch %D11.5
    Williams %R-94.5
    ROC (10d)-9.8%
    Momentum-7.75
    CCI (20d)-202.7
    MFI (14d)42.1

    Volatility Measures

    ATR (14d)$3.83(5.3%)
    StdDev (20d)3.21
    Hist Vol50.8%(High)

    Volume Flow

    VWAP$71.57
    OBV-2.6M
    AD Line-3.8M
    CMF (20d)-0.036

    Volume Metrics

    Avg Vol (20d)139.7K
    Vol Ratio0.4x(Low)
    VWMA (20d)$78.96

    Pivot Points

    R3$76.20
    R2$75.26
    R1$74.03
    Pivot Point$73.09
    S1$71.87
    S2$70.93
    S3$69.70

    Advanced Oscillators

    TSI-0.63
    Ultimate Osc37.7
    KST56.33

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$19,973$20,130$19,772$12,212$11,638N/AN/AN/A$18,113$18,112$18,113$18,112
    Gross Profit$-19,973$-20,130$-19,772$-12,212$-11,638N/AN/AN/A$-18,113$-18,112$-18,113$-18,112
    Operating Expenses$11.71M$15.55M$6.90M$5.66M$3.30M$3.35M$1.62M$791,310$-234,742$558,062$1.70M$1.55M
    R&D$9.50M$13.27M$5.66M$4.78M$2.69M$2.56M$1.05M$416,055$566,749$105,180$1.23M$1.09M
    SG&A$0$2.13M$990,110$603,962$479,260$589,820$462,728$346,012$320,644$363,595$364,581$422,564
    Operating Income$-11,733,107$-15,569,156$-6,904,082$-5,664,542$-3,296,310$-3,352,081$-1,624,651$-791,310$234,742$-558,062$-1,698,998$-1,550,479
    Interest Income$0$2.69M$818,265$529,538$476,231$509,381$4,318$6,007$14,987$0$0$0
    Interest Expense$4,174$5,592$6,572$0$1.95M$0$0$0$1,241$2,126$2,971$3,786
    Income Before Tax$-2,461,807$-10,633,956$-7,565,318$-4,085,603$-5,242,970$-2,950,385$49,610$-773,441$229,903$-574,141$-1,684,267$-1,527,998
    Income Tax Expense$0$0$0$185,149$0$0$0$0$-4$-2$-14,731$-57,934
    Net Income$-2,461,807$-10,633,956$-7,565,318$-4,085,603$-5,242,970$-2,950,385$49,610$-773,441$229,903$-574,141$-1,684,267$-1,527,998
    EBITDA$-11,713,133$-10,608,234$-7,545,529$-4,068,594$-5,227,125$-3,329,600$71,143$-754,422$248,016$-556,029$-1,666,154$22,481
    EBIT$-11,733,106$-10,628,364$-7,565,318$-4,085,603$-5,242,970$-3,352,081$49,610$-773,441$229,903$-574,141$-1,684,267$-1,527,998
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DRUG

    News

    Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of "Buy" from Analysts

    Bright Minds Biosciences Inc. (NASDAQ:DRUG) has received an average "Buy" recommendation from analysts, with a consensus 12-month price target of $143.83. The company, a clinical-stage biotechnology firm focusing on mental health and neurodegenerative disorders, reported better-than-expected quarterly earnings and has seen increased institutional investment, although its stock price recently experienced a slight dip.

    MarketBeat•8/25/26•
    Bullish

    Wall Street Zen Upgrades Bright Minds Biosciences (NASDAQ:DRUG) to Hold

    Wall Street Zen upgraded Bright Minds Biosciences (NASDAQ:DRUG) from "Sell" to "Hold," while the broader analyst consensus remains "Buy" with an average price target of $143.83. Despite being unprofitable, the company exceeded quarterly loss expectations. Analysts generally expect narrowed losses through 2029 and profitability by 2030, though the company's valuation hinges on its clinical-stage drug pipeline.

    MarketBeat•8/22/26•
    Neutral

    Bright Minds Biosciences Stock Falls 4.60% as Investors Weigh BMB-101 Clinical Progress Against Biotech Development Risk

    Bright Minds Biosciences Inc. (CSE:DRUG) experienced a 4.60% stock decline due to investor concerns about the inherent uncertainties in clinical-stage biotechnology development, particularly regarding its lead investigational drug, BMB-101. The company's valuation is heavily tied to the clinical success of BMB-101 for neurological disorders like epilepsy, making it highly sensitive to trial results, regulatory progress, and financing. The article highlights that despite the potential, the stock's performance reflects the significant risks associated with developing new therapies and the need for strong clinical data to drive future valuation.

    kalkine.ca•8/21/26•
    Bearish

    H.C. Wainwright reiterates Bright Minds stock rating at buy

    H.C. Wainwright has reiterated a Buy rating and a $145 price target for Bright Minds Biosciences Inc. following the company's Q3 2026 results. The biotech firm has shown significant growth with a 97% return over the past year, and analysts remain bullish, with price targets up to $221. Preparations for future registrational trials for BMB-101 are ongoing, and the company is also advancing its Phase 2 trial for Prader-Willi syndrome.

    Investing.com•8/20/26•
    Bullish

    Bright Minds Biosciences (NASDAQ:DRUG) Earns "Buy" Rating from HC Wainwright

    HC Wainwright has reaffirmed its "Buy" rating for Bright Minds Biosciences (NASDAQ:DRUG) with a $145 price target, suggesting a 71% upside. Other analysts also hold a positive outlook, with an average target price of $143.83. The company recently surpassed EPS estimates and institutional investors maintain significant holdings, with several increasing their positions.

    MarketBeat•8/19/26•
    Bullish

    Frequently Asked Questions About DRUG

    Does DRUG pay dividends?
    Bright Minds Biosciences Inc (DRUG) does not currently pay a regular dividend.
    What is DRUG's market cap?
    Bright Minds Biosciences Inc (DRUG) has a market capitalization of $714.42M with a current stock price of $71.73.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In